Screening Prescription Drugs for Possible Carcinogenicity: Eleven to Fifteen Years of Follow-up

Cancer Research

Volumn 49, Issue 20, 1989, Pages 5736-5747

  Selby, Joseph V ^a   Friedman, Gary D ^a   Fireman, Bruce H ^a  

^a DIVISION OF RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMPICILLIN; ANTACID AGENT; ANTIBIOTIC AGENT; ANTIHISTAMINIC AGENT; BARBITURIC ACID DERIVATIVE; BELLADONNA ALKALOID; BRONCHODILATING AGENT; CODEINE IODIDE; CYPROHEPTADINE; DEXCHLORPHENIRAMINE; DIGITALIS; ERYTHROMYCIN; ESTROGEN; FOLIC ACID; GESTAGEN; MAGALDRATE; NEOMYCIN; NONSTEROID ANTIINFLAMMATORY AGENT; ORAL CONTRACEPTIVE AGENT; PENTAZOCINE; PENTOBARBITAL; PHENYLBUTAZONE; PHENYTOIN; POLYMYXIN; SECOBARBITAL; SENNA; SPIRONOLACTONE; SULFONAMIDE; TETRACYCLINE; TRIHEXYPHENIDYL;

CANCER RISK; CARCINOGENICITY; CONTROLLED STUDY; DRUG INDUCED CANCER; DRUG SCREENING; FEMALE; FOLLOW UP; HIGHER PLANT; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; PRESCRIPTION; PRIORITY JOURNAL; SIDE EFFECT;

ANTIBIOTICS; ATROPA BELLADONNA; CARCINOGENS; ERYTHROMYCIN; ESOPHAGEAL NEOPLASMS; FOLIC ACID; FOLLOW-UP STUDIES; GASTROINTESTINAL NEOPLASMS; LUNG NEOPLASMS; LYMPHOMA, NON-HODGKIN; MULTIPLE MYELOMA; NEOMYCIN; NEOPLASMS; PHARMACEUTICAL PREPARATIONS; PHENYLBUTAZONE; PIPERIDONES; PLANTS, MEDICINAL; PLANTS, TOXIC; POLYMYXIN B; PROPANTHELINE; SECOBARBITAL; SULFATHIAZOLES; SUPPORT, U.S. GOV'T, P.H.S.; VITAMINS;

EID: 0024433857     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Farber, E. Chemical carcinogenesis: a current biological perspective. Carcinogenesis (Lond.), 5: 1–5, 1984.
2. Friedman, G. D., and Ury, H. K. Initial screening for carcinogenicity of commonly used drugs. J. Natl. Cancer Inst., 65: 723–733, 1980.
3. Friedman, G. D., and Ury, H. K. Screening for possible drug carcinogenicity: second report of findings. J. Natl. Cancer Inst., 71: 1165–1175, 1983.
4. Friedman, G. D. Monitoring of drug effects in outpatients: development of a program to detect carcinogenesis. In: H. Ducrot, M. Goldberg, and R. Hoigne (eds.), Computer Aid to Drug Therapy and to Drug Monitoring, pp. 55–62, Amsterdam: North Holland, 1978.
5. Collen, M. F., and Davis, L. F. The multitest laboratory in health care. J. Occup. Med., 77: 355–360, 1969.
6. Arellano, M. G., Peterson, G. R., Petitti, D. B., and Smith, R. E. The California Automated Mortality Linkage System (CAMLIS). Am. J. Public Health, 74: 1324–1330, 1984.
7. Friedman, G. D. Pharmacoepidemiology in the Kaiser Permanente Medical Care Program: northern California and other regions. In: B. L. Strom (ed.), Pharmacoepidemiology: The Science of Postmarketing Drug Surveillance. New York: Churchill-Livingstone, in press, 1989.
8. Seltzer, C. C., Friedman, G. D., and Siegelaub, A. B. Smoking and drug consumption. Am. J. Public Health, 64: 466–473, 1974.
9. Weinberg, E. D. Iron, infection, and neoplasia. Clin. Physiol. Biochem., 4: 50–60, 1986.
10. Schottenfeld, D., and Fraumeni, J. F., Jr. Cancer Epidemiology and Prevention, pp. 596–623. Philadelphia: W. B. Saunders Company, 1982.
11. Friedman, G.D. Barbiturates and lung cancer in humans. J. Natl. Cancer Inst., 67: 291–295, 1981.
12. Friedman, G. D. Barbiturates, benzodiazepines and lung cancer [Letter]. Int. J. Epidemiol., 12: 375–376, 1983.
13. Pfeifer, H. J., Greenblatt, D. J., and Friedman, P. Effects of three antibiotics on theophylline kinetics. Clin. Pharmacol. Ther., 26: 36–40, 1979.
14. Ptachcinski, R. J., Carpenter, B. J., Burckart, G. J., et al. Effect of erythromycin on cyclosporine levels [Letter]. N. Engl. J. Med., 313: 1416–1417, 1985.
15. Harvey, S. C. Hypnotics and sedatives. In: A. G. Gilman, L. S. Gilman, A. Gilman (eds.), The Pharmacologic Basis of Therapeutics, Sixth Edition, pp. 339–375. New York: Macmillan, 1980.
16. Meakawa, A., Onodera, H., Tanigawa, H., et al. Long-term studies on carcinogenicity and promoting effect of phenylbutazone on DONRYU rats. J. Natl. Cancer Inst., 79: 577–584, 1987.
17. Friedman, G. D. Phenylbutazone, musculoskeletal disease, and leukemia. J. Chronic Dis., 35: 233–243, 1982.
18. Peraino, C., Fry, R. J., Staffeldt, E., and Kisieleski, W. E. Effects of varying the exposure to phénobarbital on its enhancement of 2-acetylaminofluorine-induced hepatic tumorigenesis in the rat. Cancer Res., 33: 2701–2705, 1973.
19. International Agency for Research on Cancer. Phénobarbital and phénobarbital sodium. Some miscellaneous pharmaceutical substances. IARC Mongr. Eval. Carcinog. Risk Chem. Man, 13: 157–181, 1977.
20. Gelboin, H. V. Cancer susceptibility and carcinogen metabolism. N. Engl. J. Med., 297: 384–386, 1977.
21. MacMahon, B. Phénobarbital: Epidemiological evidence. IARC Scientific Publ., 65: 153–158, 1985.
22. International Agency for Research on Cancer. Sulfamethoxazole. IARC Mongr. Eval. Carcinog. Risk Chem. Hum., 24: 285–295, 1977.
23. Zheng, W., Blot, W. J., and Liao, M. L., et al. Lung cancer and prior tuberculosis infection in Shanghai. Br. J. Cancer, 40: 501–504, 1987.
24. Baron, J. A. Smoking and estrogen-related disease. Am. J. Epidemiol., 119: 9–22, 1984.
25. Weiss, N. S., Farewell, V. T., and Szekely, D. R., et al. Oestrogens and endometrial cancer effect of other risk factors on the association. Maturitas, 2: 185–190, 1980.
26. Vena, J. E., Bona, J. R., Byers, T. E., et al. Allergy-related diseases and cancer: an inverse association. Am. J. Epidemiol., 122: 66–74, 1985.
27. Knekt, P., Aromaa, A., Macetela, J., et al. Serum vitamin E and risk of cancer among Finnish men during a 10-year follow-up. Am. J. Epidemiol., 727: 28–41, 1988.
28. Karmali, R. A., Volkman, A., and Muse, P. The influence of diazepam administration in rats bearing the R3230AC mammary carcinoma. Prostaglandins Med., 3: 193–198, 1979.
29. Kaufman, D. W., Shapiro, S., and Slone, D., et al. Diazepam and the risk of breast cancer. Lancet, 1: 537–539, 1982.
30. Kleinerman, R. A., Brinton, L. A., Hoover, R., and Fraumeni, J. F., Jr. Diazepam use and progression of breast cancer. Cancer Res., 44: 1223–1225, 1984.
31. Wallace, R. B., Sherman, B. M., and Bean, J. A. A case-control study of breast cancer and psychotropic drug use. Oncology (Basel), 39: 279–283, 1982.
32. Balo, J. Role of hydrazine in carcinogeneisis. Adv. Cancer Res., 30: 151–164, 1979.
33. Kaufman, D. W., Kelly, J. P., and Rosenberg, L., et al. Hydralazine and breast cancer. J. Natl. Cancer Inst., 78: 243–246, 1987.
34. Li, F. P., Willard, D. R., Goodman, R., and Vawter, G. Malignant lymphoma after diphenylhydantoin (dilantin) therapy. Cancer (Phila), 36: 1359–1362, 1975.
35. Grob, P. J., and Herold, G. E. Immunological abnormalities and hydantoins. Br. Med. J., 16: 561–563, 1972.
36. Friedman, G. D. Multiple myeloma: relation to propoxyphene and other drugs, radiation and occupation. Int. J. Epidemiol., 75: 424–426, 1986.
37. Kochar, A. S. Development of malignant melanoma after levodopa therapy for Parkinson's disease: report of a case and review of the literature. Am. J. Med., 79: 119–121, 1985.
38. Broden, G., and Bengtsson, L. Biliary carcinoma associated with methyldopa therapy. Acta Chir. Scand. Supp., 500: 7–12, 1980.
39. Strom, B. L., Hibberd, P. L., and Stolley, P. No evidence of association between methyldopa and biliary carcinoma. Int. J. Epidemiol., 14: 86–90, 1985.